What type of study is this?

This is a Pre-Registered Trial study (also classified as: Experimental Study).

October 9, 2025

CAR-ving a Path: Metalloprotease-Engineered CAR T Cells Tunnel through Solid Tumors

Key Points

Engineering CAR T cells with metalloproteinase 7 improves tumor penetration and functionality, showcasing innovative cellular modifications.
The introduction of osteopontin-b alongside metalloproteinase 7 shows enhanced effectiveness in preclinical models of solid tumors.
The study provides evidence that targeting the tumor microenvironment can lead to better CAR T-cell therapy outcomes without increased toxicity risks.
These findings suggest a new direction for CAR T-cell design by incorporating extracellular matrix remodeling capabilities for solid tumors.

Abstract

Abstract Overcoming the physical barriers of the tumor microenvironment remains a major obstacle for chimeric antigen receptor (CAR) T-cell therapy in solid tumors. In this issue, Van Pelt and colleagues show that engineering GD2-targeting CAR T cells to express matrix metalloproteinase 7 and osteopontin-b enhances their ability to infiltrate tumors rich in extracellular matrix. These modifications improve functionality in preclinical models without increasing off-target toxicity. The findings highlight a promising strategy to design CAR T cells with extracellular matrix–remodeling capabilities. See related article by Van Pelt et al., p. XX .

Mark Helpful

Bookmark

Relay